Literature DB >> 21713520

Significance of persistence of antibodies against Leishmania infantum in Sicilian patients affected by acute visceral leishmaniasis.

Pasquale Mansueto1, Ilenia Pepe, Aurelio Seidita, Francesca Scozzari, Giustina Vitale, Francesco Arcoleo, Inglese Elvira, Enrico Cillari, Giovam Battista Rini, Nicola Napoli, Salvatore Di Rosa, Serafino Mansueto, Gaetana Di Fede.   

Abstract

The background of this article is as follows: Few data are available about the persistence of serum-specific IgG antibodies to L. infantum after acute VL. The objective of this article is to evaluate the persistence of antibodies against L. infantum in patients healed from acute VL, and the kinetic of the same antibodies observed in 2 cases of VL relapse and 2 cases of resistance to therapy. The methods which we used to obtain our objective are the following: 55 apparently immunocompetent, HIV-negative patients were examined for antibodies to L. infantum by IFAT over 14 years period, and we got the following results: Serum-specific IgG antibodies titers decrease slowly, but constantly. In the patients with a diagnosis of VL relapse, the kinetic of antibodies was characterized by an initial reduction, and a subsequent antibody levels rapidly increase, while in the patients with a clinical and parasitological diagnosis of VL not responding to specific therapy, we demonstrated persistent high level of antibodies to L. infantum. Finally, we conclude that specific antibodies to L. infantum might persist for many years, and decrease slowly, but steadily. The persistence of these specific antibodies is not related to poor therapeutic response or prognosis, but an acute increase in their levels might be a sentinel of a VL relapse, while persistence of high antibody levels could suggest a resistance to therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21713520     DOI: 10.1007/s10238-011-0150-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  24 in total

Review 1.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

Authors:  François Chappuis; Shyam Sundar; Asrat Hailu; Hashim Ghalib; Suman Rijal; Rosanna W Peeling; Jorge Alvar; Marleen Boelaert
Journal:  Nat Rev Microbiol       Date:  2007-11       Impact factor: 60.633

2.  The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features.

Authors:  A M Musa; E A G Khalil; M A Raheem; E E Zijlstra; M E Ibrahim; I M Elhassan; M M Mukhtar; A M El Hassan
Journal:  Ann Trop Med Parasitol       Date:  2002-12

3.  Persistence of elevated levels of galactosyl-alpha(1-3)galactose antibodies in sera from patients cured of visceral leishmaniasis.

Authors:  J L Avila; M Rojas; L García
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

4.  [Behavior of antibodies (titrated by means of the immunofluorescence test) in visceral leishmaniasis treated by antimony therapy].

Authors:  G Cascio
Journal:  Pediatria (Napoli)       Date:  1970-07-30

5.  Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen.

Authors:  Sarman Singh; Veena Kumari; Niti Singh
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

6.  Immunoglobulin subclass distribution and diagnostic value of Leishmania donovani antigen-specific immunoglobulin G3 in Indian kala-azar patients.

Authors:  K Anam; F Afrin; D Banerjee; N Pramanik; S K Guha; R P Goswami; P N Gupta; S K Saha; N Ali
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 7.  Recent advances in the diagnosis of leishmaniasis.

Authors:  S Singh; R Sivakumar
Journal:  J Postgrad Med       Date:  2003 Jan-Mar       Impact factor: 1.476

Review 8.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

9.  Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis.

Authors:  S Singh; A Gilman-Sachs; K P Chang; S G Reed
Journal:  J Parasitol       Date:  1995-12       Impact factor: 1.276

10.  Persistence of human leishmanial antibodies in an endemic area of visceral leishmaniasis in El Agamy, Egypt.

Authors:  M V Londner; F M Feinsod; R Faris; G Rosen; S el Said; A J Saah
Journal:  Eur J Epidemiol       Date:  1988-12       Impact factor: 8.082

View more
  3 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Development of an Immunochromatographic Test for Diagnosis of Visceral Leishmaniasis Based on Detection of a Circulating Antigen.

Authors:  Chun-hua Gao; Yue-tao Yang; Feng Shi; Jun-yun Wang; Dietmar Steverding; Xia Wang
Journal:  PLoS Negl Trop Dis       Date:  2015-06-30

3.  Clinical and Immunological Analysis of Cutaneous Leishmaniasis before and after Different Treatments.

Authors:  José A O'Daly; Humberto M Spinetti; Joe Gleason; María B Rodríguez
Journal:  J Parasitol Res       Date:  2013-06-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.